Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours Β· Estimated delivery Sep 24 - Sep 29
Medicare Part D coverage expansion: The proposed CMS rule allowing Medicare Part D plans to cover anti-obesity medications would make 31 million Medicare beneficiaries with obesity eligible for semaglutide and tirzepatide, representing a USD 55.8 billion annual drug spend potential at 15% initial penetration
muciniphila microencapsulation applications
Semaglutide is a GLP-1 receptor agonist that can help regulate appetite and blood sugar
Should I stop my GLP-1 medication before a colonoscopy
Understanding which foods to limit may help patients manage their treatment more effectively
Important markers to monitor include apolipoprotein B (ApoB), a protein found on LDL particles that can cause plaque buildup in arteries, and glycoprotein acetylation (GlycA), which can indicate systemic inflammation and heart health risk
US$ 28.82
US$ 24.07
US$ 28.50
US$ 21.62
US$ 28.25
US$ 26.94
